Countdown to Partnering - John Carroll, Editor of Fierce Biotech

  • Recommend
  • Tweet
  • Print
  • Email

John Carroll, editor of Fierce Biotech, shares what he won't miss at the 2011 BIO International Convention.

TOP TEN 'CAN'T MISS' BREAKOUT SESSIONS

201 - FDA – TOWNHALL (Achieving Regulatory Approval and Compliance) 
Wednesday
2:00 pm - 3:30 pm

  • Outline key FDA organizational and policy initiatives.
  • Present FDA's views on critical topics such as FDAAA/PDUFA V, drug safety, transparency, and Critical Path regulatory science programs.
  • Stimulate interactive discussion with respect to the initiatives and issues presented.

97 - Personalized Oncology: The Emergence of Personalized Medicine Strategies in Oncology Clinical Development and Deal Making (Diagnostics & Personalized Medicine)
Tuesday
2:00 pm - 3:30 pm

  • Understand scientific and market trends toward personalized medicine in oncology.
  • Understand technology challenges of translating biomarkers into clinical use.
  • Understand regulatory challenges of translating biomarkers into clinical use and into the marketplace.

261 - Addressing the Major Medical Challenges of Today with Personalized Medicine: Cancer, Diabetes and Brain Injury (Diagnostics and Personalized Medicine) 
Tuesday 
10:00 am - 11:30 am

  • Review the latest achievements in developing targeted anti-cancer vaccines. Learn the potential new approaches to diabetes diagnosis and treatment based on understanding of the genetic causes of the disease.
  • Learn how the development of biomarkers for TBI can impact diagnosis, management and treatment of brain injured patients.

199 - Starting Up Biotechs in the New Normal World (Finance)
Wednesday
10:00 am – 11:30 am

  • Provide CEO and VC views on how biotech venture fundraising has changed between early 2008 and 2011.
  • Review non-VC funding options for start-up biotechs.
  • Provide an interactive forum for entrepreneurs to ask questions.

196 - Wait, Our Model Isn't Dead! We Just Need to Evolve (Finance) 
Tuesday 
2:00 pm - 3:30 pm

  • Describe how and why VC models have evolved.
  • Offer insights on how to successfully navigate the new venture landscape.
  • Explain VC valuation methods and investing models.

194 - Financing Beyond the Lead Compound: Attracting Funding for Multiproduct Platforms (Finance) 
Tuesday
10:00 am - 11:30 am

  • Show how to build a business plan that conveys value of the company, beyond a lead candidate.
  • Describe how to create strategies that attract VC financing and capitalize on the value of product.
  • Showcase the potential of the value proposition for the platform and company.

199 - Starting Up Biotechs in the New Normal World (Finance) 
Wednesday 
10:00 am – 11:30 am

  • Provide CEO and VC views on how biotech venture fundraising has changed between early 2008 and 2011.
  • Review non-VC funding options for start-up biotechs.
  • Provide an interactive forum for entrepreneurs to ask questions.

200 - Collaborations and Strategies to Crossing the Valley of Death to Fund Innovative Medicines (Finance) 
Wednesday
2:00 pm - 3:30 pm

  • Explore strategies to overcome the challenges and bottlenecks of drug development.
  • Highlight current and future projects aimed at transforming drug development.
  • Discuss how unique partnerships can bring innovative medicines to patients worldwide.

95 - Innovative Collaborations: Deal Structures for Nonprofit/For-Profit Collaborations (Biotech Patenting and Tech Transfer) 
Thursday, June 30, 2011
8:30 am - 9:45 am

  • Describe successful industry collaborations with nonprofits and drafting those clauses in your agreement.
  • Explain how collaboration terms vary when one or both of the parties is a non-U.S. entity.
  • List structures and terms to avoid in the interest of a successful collaboration.

188 - The Changing BD Environment: Overcoming Our Past to Succeed in the Future (Business Development) 
Tuesday 
2:00 pm - 3:30 pm

  • Explain the dynamics (type, economics, timing, roles) driving biotech/pharma collaborations.
  • Conceptualize novel approaches to biotech and pharma collaborations.
  • Identify key deal showstoppers from either a historical or novel transaction approach.
Hide Date: 
Show